Description: Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Home Page: www.annexonbio.com
ANNX Technical Analysis
1400 Sierra Point Parkway
Brisbane,
CA
94005
United States
Phone:
650 822 5500
Officers
Name | Title |
---|---|
Mr. Douglas Love J.D., Esq. | CEO, Pres & Director |
Dr. Larry C. Mattheakis Ph.D. | Exec. VP & Chief Scientific Officer |
Dr. Ted Yednock Ph.D. | Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board |
Dr. Arnon Rosenthal Ph.D. | Founder |
Ms. Jennifer Lew | Exec. VP & CFO |
Miriam Mason | Sr. VP of Corp. Communications |
Mr. Michael Overdorf M.B.A. | Exec. VP & Chief Bus. Officer |
Henk-Andre Kroon M.D. | Sr. VP of Translational Medicine |
Mirella Villa Del Toro | Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.9979 |
Price-to-Sales TTM: | 0 |
IPO Date: | 2020-07-24 |
Fiscal Year End: | December |
Full Time Employees: | 83 |